Oppenheimer & Co. Inc. Purchases 53,526 Shares of Pfizer Inc. (NYSE:PFE)

Oppenheimer & Co. Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 8.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 658,388 shares of the biopharmaceutical company’s stock after buying an additional 53,526 shares during the period. Oppenheimer & Co. Inc.’s holdings in Pfizer were worth $19,054,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new position in Pfizer during the 1st quarter worth about $315,000. GSA Capital Partners LLP bought a new position in Pfizer during the 1st quarter worth about $439,000. Koshinski Asset Management Inc. increased its holdings in Pfizer by 20.5% during the 1st quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock worth $673,000 after purchasing an additional 4,130 shares in the last quarter. Dearborn Partners LLC increased its holdings in Pfizer by 18.4% during the 1st quarter. Dearborn Partners LLC now owns 32,683 shares of the biopharmaceutical company’s stock worth $907,000 after purchasing an additional 5,077 shares in the last quarter. Finally, Private Management Group Inc. increased its holdings in Pfizer by 270.7% during the 1st quarter. Private Management Group Inc. now owns 26,579 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 19,409 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on PFE shares. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. UBS Group raised their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Performance

PFE stock traded down $0.06 during mid-day trading on Wednesday, hitting $26.13. 4,382,206 shares of the company were exchanged, compared to its average volume of 37,573,504. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The business has a 50 day simple moving average of $28.80 and a 200-day simple moving average of $28.68. The stock has a market capitalization of $148.08 billion, a PE ratio of 35.32, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm earned ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.43%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.